Fiche publication
Date publication
octobre 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher
Tous les auteurs :
Nahon S, Rastkhah M, Ben Abdelghani M, Soumoudronga RF, Gasnereau I, Labourey JL
Lien Pubmed
Résumé
PURPOSE: Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio(R)-biosimilar of Neupogen(R) (G-CSF; filgrastim)-in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients. METHODS: We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy. RESULTS: One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio(R) were pain, in particular bone pain. No serious adverse event related to Zarzio(R) was reported. CONCLUSION: The results obtained in real-life conditions confirm that Zarzio(R) is efficient and well tolerated in cancer patients.
Référence
Support Care Cancer. 2015 Oct 27.
